Impact of Whole‐Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131I‐Metaiodobenzylguanidine (MIBG)

M. Trieu,S. DuBois,E. Pon,L. Nardo,R. Hawkins,A. Marachelian,C. Twist,Julie R. Park,K. Matthay
DOI: https://doi.org/10.1002/pbc.25816
2016-03-01
Pediatric Blood & Cancer
Abstract:131I‐metaiodobenzylguanidine (131I‐MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor‐specific uptake, the treatment with 131I‐MIBG results in whole‐body radiation exposure. Our aim was to correlate whole‐body radiation dose (WBD) from 131I‐MIBG with tumor response, toxicities, and other clinical factors.
What problem does this paper attempt to address?